Atara Biotherapeutics (ATRA) ‘neutral’ rating confirmed by HC Wainwright

HC Wainwright maintained its neutral rating on the stock Atara Biotherapeutics (NASDAQ:ATRA – Free Report) – according to Benzinga, in a report published on Wednesday morning.

On Friday, April 5, StockNews.com increased its recommendation for Atara Biotherapeutics shares from a sell rating to a hold rating.

Get our latest stock analysis for Atara Biotherapeutics

Atara Biotherapeutics stock performance

ATRA shares opened at $0.70 on Wednesday. The company has a market capitalization of $84.27 million, a price-to-earnings ratio of -0.33 and a beta of 0.70. Atara Biotherapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.54. The company has a 50-day moving average price of $0.68 and a 200-day moving average price of $0.67.

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.14. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. The company had revenue of $27.36 million for the quarter, compared to analyst estimates of $27.00 million. Equity research analysts predict that, as a group, Atara Biotherapeutics will post earnings per share of -1.22 for the current year.

Insider buying and selling at Atara Biotherapeutics

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 81,506 shares of the company’s stock in a transaction on Thursday, May 16. The shares were sold at an average price of $0.62, for a total transaction amount of $50,533.72. Following the transaction, the CEO now directly owns 1,829,146 shares of the company’s stock, valued at approximately $1,134,070.52. The sale was disclosed in a legal filing filed with the SEC, which can be accessed through the SEC’s website. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 81,506 shares of the company’s stock in a transaction on Thursday, May 16. The shares were sold at an average price of $0.62, for a total transaction amount of $50,533.72. Following the transaction, the CEO now directly owns 1,829,146 shares of the company’s stock, valued at approximately $1,134,070.52. The sale was disclosed in a legal filing filed with the SEC, which can be accessed through the SEC’s website. Additionally, Vice President Anhco Nguyen sold 42,899 shares of the company’s stock on Thursday, May 16. The shares were sold at an average price of $0.62, for a total transaction amount of $26,597.38. Following the transaction, the executive vice president now directly owns 898,498 shares of the company’s stock, valued at $557,068.76. The announcement of this sale can be found here. Over the last ninety days, insiders have sold 188,643 shares of company stock worth $120,518. Currently, company insiders own 3.70% of the shares.

Institutional trading of Atara biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings in ATRA. Private Advisor Group LLC increased its position in shares of Atara Biotherapeutics by 53.0% during the 3rd quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 33,063 shares during the period. Staley Capital Advisers Inc. in the third quarter increased its position in Atara Biotherapeutics shares by 33.3%. Staley Capital Advisers Inc. now owns 1,000,000 shares of the biotechnology company’s stock valued at $1,480,000 after purchasing an additional 250,000 shares during the period. 683 Capital Management LLC increased its position in shares of Atara Biotherapeutics by 20.0% during the 3rd quarter. 683 Capital Management LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $1,776,000 after purchasing an additional 200,000 shares during the period. Redmile Group LLC increased its position in Atara Biotherapeutics by 3.8% during the third quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after purchasing an additional 232,690 shares in the last quarter. Finally, Josh Arnold Investment Consultant LLC increased its position in Atara Biotherapeutics by 17.6% during the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 30,000 shares in the last quarter. 70.90% of the shares are owned by hedge funds and other institutional investors.

Atara Biotherapeutics company profile

(Get the free report)

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic malignancies and autoimmune diseases in the United States. Its lead product is Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of EBV-induced post-transplant lymphoproliferative disease and nasopharyngeal cancer.

Featured Stories

Get Atara Biotherapeutics news and ratings every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Atara Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.